{"id":129249,"date":"2021-10-20T06:22:54","date_gmt":"2021-10-20T13:22:54","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2021\/10\/anti-amyloid-antibody-receives-breakthrough-therapy-designation-in-us"},"modified":"2021-10-20T06:22:54","modified_gmt":"2021-10-20T13:22:54","slug":"anti-amyloid-antibody-receives-breakthrough-therapy-designation-in-us","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2021\/10\/anti-amyloid-antibody-receives-breakthrough-therapy-designation-in-us","title":{"rendered":"Anti-amyloid antibody receives Breakthrough Therapy Designation in US"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/anti-amyloid-antibody-receives-breakthrough-therapy-designation-in-us.jpg\"><\/a><\/p>\n<p>Roche\u2019s gantenerumab is an anti-amyloid beta antibody developed for subcutaneous administration in Alzheimer\u2019s disease patients.<\/p>\n<p><a href=\"https:\/\/www.roche.com\/\" target=\"_blank\" rel=\"noopener\">Roche\u2019s<\/a> gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) for the treatment of people living with <a href=\"https:\/\/www.europeanpharmaceuticalreview.com\/news\/159290\/alzheimers-treatment-lowers-tau-by-nearly-50-percent-in-phase-i-trials\/\" target=\"_blank\" rel=\"noopener\">Alzheimer\u2019s disease (AD<\/a><a href=\"https:\/\/www.europeanpharmaceuticalreview.com\/news\/159290\/alzheimers-treatment-lowers-tau-by-nearly-50-percent-in-phase-i-trials\/\" target=\"_blank\" rel=\"noopener\">)<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roche\u2019s gantenerumab is an anti-amyloid beta antibody developed for subcutaneous administration in Alzheimer\u2019s disease patients. Roche\u2019s gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) for the treatment of people living with Alzheimer\u2019s disease (AD).<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-129249","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/129249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=129249"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/129249\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=129249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=129249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=129249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}